Ignite Creation Date:
2024-05-06 @ 3:17 AM
Last Modification Date:
2024-10-26 @ 11:31 AM
Study NCT ID:
NCT02257424
Status:
COMPLETED
Last Update Posted:
2022-01-20
First Post:
2014-10-02
Brief Title:
Dabrafenib Trametinib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma
Sponsor:
Abramson Cancer Center at Penn Medicine
Organization:
Abramson Cancer Center at Penn Medicine
Study Overview
Official Title:
BRAF Autophagy and MEK Inhibition in Metastatic Melanoma A Phase III Open-Label Trial of Dabrafenib Trametinib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma
Status:
COMPLETED
Status Verified Date:
2022-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
BAMM
Brief Summary:
The primary purpose of this study is to determine the maximum tolerated dose MTD and preliminary safety of hydroxychloroquine HCQ when administered in conjunction with oral dabrafenib and trametinib DT in patients with advanced BRAF mutant melanoma
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None